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Background: Previous studies found an association of greater adherence to placebo medication with better
outcomes. The present study tested whether this association was explained by any of the following factors: 1)
adherence to other medications, 2) healthcare behaviors, 3) disease risk, or 4) predicted degree of adherence. Data
included information on more than 800 risk factors from 27,347 subjects in two randomized controlled trials of
hormone therapy in the Women's Health Initiative.
Results: Greater adherence to placebo was not associated with colon cancer but was substantially and significantly
associated with several diverse outcomes: death, myocardial infarction, stroke, and breast cancer. Adherence to
hormone therapy was only weakly associated with outcomes. The WHI risk factors only poorly predicted degree of
adherence, R2 < 4%. No underlying factors accounted for the association between placebo adherence and
outcome.
Conclusion: The results suggest that adherence to placebo is a marker for important risk factors that were not
measured by WHI. Once identified these risk factors may be used to increase the validity of observational studies of
medical treatment by reducing unmeasured confounding.
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Greater adherence to placebo is associated with lower
rates of cardiovascular disease and mortality [1-5]. It has
been suggested [6,7] that this association is caused by
factors confounded with placebo adherence such as bet-
ter adherence to active medications or preventive
services [8,9], less comorbidity and better functional sta-
tus [10], and decreasing likelihood of risky behaviors
[11]. However, the importance of these factors as an ex-
planation of the healthy adherer effect has not been
demonstrated.
The present study evaluates whether the association of
outcome and adherence is due to factors commonly
measured in epidemiological studies or whether it is ne-
cessary to identify new risk factors that influence both
adherence and outcomes. For this study we use the com-
prehensive dataset obtained by the Women’s Health Ini-
tiative (WHI). We searched for factors that predict* Correspondence: hartzarthur@gmail.com
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reproduction in any medium, provided the oradherence and might be confounded with the associ-
ation of adherence with outcomes.
Methods
Several analytic approaches were used to assess the asso-
ciation between adherence and disease: 1) Adherence
was tested for an association with several outcomes. If
adherence has a much stronger association with cardio-
vascular diseases than cancers, it would suggest that ad-
herence is associated with behaviors that influence
cardiovascular disease more than cancer. 2) Associations
between adherence and outcome were compared for
women taking medications and women not taking these
medications. Stronger associations for women taking
medications might imply that adherence to placebo is a
marker for greater adherence to other medications that
influence outcome. 3) Factors influencing adherence to
placebo were compared to factors influencing adherence
to hormone therapy. If the same factors influence both
adherence to placebo and adherence to hormones, then
these same factors are likely to influence adherence to
other medications. This is another way of evaluatingl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to other medications. 4) We screened many risk factors
for health and healthcare behaviors to assess whether
any accounted for the association between adherence
and outcomes. If this association is substantially reduced
after adjustment for certain risk factors, then the associ-
ation might be mediated by risk factors related to those
used in the adjustment.
The Women's Health Initiative study design has been
described in detail [12-14]. In brief, it was a long-term
national health study that focused on strategies for
preventing heart disease, breast and colorectal cancer,
and osteoporosis in postmenopausal women. Women
between the ages of 50 and 79 were enrolled for an ob-
servational study or randomized controlled trial (RCT)
from 1993 to 1998 at 40 clinical centers throughout the
United States. All participants signed informed consent
forms. The institutional review boards at all participating
institutions approved the study protocols and procedures.
The median follow-up time was eight years. The present
study included participants in RCTs of hormone therapy:
16 608 from the RCT of estrogen plus progesterone and
10 739 from the RCT of estrogen only.
Data
For outcome ascertainment all subjects completed semi-
annually self-administered, self-reports. Medical records
were reviewed for patients who died in the hospital, and
autopsy reports were reviewed for patients who had an
autopsy. Only the death certificates were reviewed for
patients who died outside of the hospital without an aut-
opsy. Outcomes during the follow-up period that were
evaluated in the present study included myocardial in-
farction, stroke, breast cancer, colon cancer, and death.
These outcomes were relatively common and sufficiently
diverse to show how the association of outcome with ad-
herence varies according to outcome.
The primary risk factor of interest was adherence
measured at the time of the one-year follow-up ques-
tionnaire. We chose this as our adherence measure be-
cause subsequent assessments of adherence might be
more weakly associated with the subject’s baseline
characteristics and were more likely to be influenced by
outcomes that occurred after baseline. The proportion
adherence was computed by the WHI as the number of
days for which the study medication was dispensed
minus the number of days of untaken pills divided by
the number of days between visits. The primary adher-
ence score was on a four point scale: 1) ≤80%, 2) >80%
to ≤90%, 3) >90% to ≤ 100%, and 4) >100%. Subjects
with adherence greater than 100% were those whose pill
count was less than the difference between the number
of pills provided and number prescribed. These subjects
may have lost pills, inadvertently taken extra pillsbecause of an inadequate system for tracking pills, or
intentionally took extra pills to gain a hoped for benefit.
Lost or extra pills of other subjects must have been less
than the missed doses for these subjects.
Risk factors for outcome
Prior to beginning the present study forward and back-
ward stepwise Cox proportional hazard regression was
used to select baseline risk factors for each of the
outcomes examined. More than 800 risk factors were
candidates for selection in an analysis of outcomes from
more than 150,000 women in the WHI. The risk factors
for each outcome were as follows:
Myocardial infarction: age, race, income, general
health, ability to climb stairs, current smoking, cardio-
vascular disease, systolic blood pressure, family history
of myocardial infarction, treatment for hypertension, his-
tory of myocardial infarction, treatment for diabetes,
prior coronary artery bypass surgery, and waist-hip ratio.
Stroke: age, race, income, smoking, physical function,
systolic blood pressure, cardiovascular disease, diabetes,
history of stroke, history of transient ischemic attacks,
and treatment for hypertension.
Breast cancer: age, race, history of breast cancer in
first degree relative, needle aspirations of the breast,
breast biopsy, history of hormone usage, and current
hormone use.
Colon cancer: age, waist, history of hormone use,
smoking, diabetes, and family history of colon cancer.
Death: age, general health, treatment for diabetes, his-
tory of coronary artery bypass surgery, lack of appetite,
physical function, systolic blood pressure, and years
smoked.
None of the numerous psychosocial measures available
from the WHI such as those related to life events, emo-
tional wellbeing, depression, or interpersonal relationships,
were independent risk factors for any of the outcomes
considered.
Statistical methods
One analysis examined the association of adherence with
binary variables for healthcare behaviors and education.
The strength of this association was measured by com-
paring the percentage of women who had adherence
rates greater than 90% for the two levels of the binary
variable. Significance testing of the association was
performed using a t test with adherence on a continuous
scale.
A second analysis used stepwise linear regression to
identify risk factors independently associated with adher-
ence at p<0.001. More than 800 risk factors were
candidates for inclusion in the regression equation.
Variables were retained in a regression equation only if
the statistical significance of the variable was not
Table 1 Demographic characteristics and outcomes in the
study sample
Characteristics Categories N % of
Total
Age (yrs) 49 to 55 4510 16.52
56 to 69 16,643 60.96
70 to 81 6147 22.52
Race Caucasian 21,997 80.58
Non-Caucasian 5303 19.42
Education level No post high school 7994 29.28
Post high school 11,020 40.37
College graduate 8286 30.35
Income < $35,000 13,348 48.89
35,000 to 75,000 9479 34.72
≥ 75,000 1467 10.77
Don’t know 1533 5.62
Insurance type
(could have more than
1 type)






RCT of estrogen plus
progesterone
16,608 60.73
RCT of estrogen alone 10,739 39.27
Perecent adherence
≤ 50% 2064 7.6%
> 50% to ≤ 80% 3090 11.4%
> 80% to ≤ 90% 3195 11.76
> 90% to ≤ 100% 16,024 58.97
> 100% 2792 10.27
Outcomes
Myocardial infarction 950 3.49
Stroke 694 2.55
Breast cancer 941 3.44
Colon cancer 258 0.94
Death 1645 6.02
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the variable instead of the raw value (i.e., the association
with adherence did not depend on extreme values of the
variable). Using these stringent criteria for significance
for inclusion in stepwise regression models protected
somewhat against including variables with a spurious as-
sociation with adherence. However, there was no adjust-
ment for multiple comparisons because we wanted to
include any characteristics that could possibly be mean-
ingful. This approach has been suggested by a leading
epidemiologist [15].
It is possible that the factors that influence adherence
to placebo differ from the factors that influence adher-
ence to hormone therapy. To test this possibility, we
added to the regression equation an interaction term of
each factor with hormone therapy. This analysis was
performed in a dataset that combined both hormone
therapy and placebo subjects.
The Cox model was used to test whether the level of
adherence was a risk factor for a given outcome after
adjusting for all of the independent baseline risk factors
for that outcome. For these analyses adherence was in
four categories and represented by three indicator
variables, one for each of the categories except for the
highest level of adherence. Therefore, the hazard ratio
associated with each level compared the risk at that level
to the risk for women at the highest level of adherence.
These risk-adjusted hazard ratios for level of adherence
were presented in one figure for the subjects taking
placebo and one for the subjects taking hormone
therapy.
As a measure of a subjects overall risk for a given out-
come we used the sum of the products of the values of
the patient’s risk factors and the respective regression
coefficients in the Cox model for that risk factor. Correl-
ation was used to test the association between adherence
and subject risk.
All statistical analyses were performed using SAS ver-
sion 9 (SAS Institute Inc, Cary, NC).
Results
As shown in Table 1 most women were ages 56 to 69,
Caucasian, had more than a high school education, and
had private insurance. Sixty-nine percent of the subjects
had adherence rates greater than 90% and 10% had rates
greater than 100%. Of the outcomes evaluated the most
common was death and the least common was colon
cancer.
Predictors of adherence
Table 2 shows the association of adherence with health-
care behaviors and education, which is often associa-
ted with healthcare behaviors. Subjects are divided into
placebo and hormone therapy arms. The percentage ofsubjects with adherence rates greater than 90% was lo-
wer for women in the hormone therapy arm of the stu-
dy (66.5%) than the placebo arm (72.0%), P<0.0001. In
both study arms the women who engaged in any of the
healthcare behaviors listed had a higher adherence rate
than women who didn’t. For women taking placebo
three healthcare behaviors (taking multivitamins, not
smoking, and greater recreational physical activity) were
associated with adherence at P<0.0001. For women on
hormone therapy taking multivitamins was the only health-
care behavior associated with higher adherence at the
P<0.0001 level.
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as determined by linear regression are shown in Table 3.
In this table subjects receiving either estrogen alone or
estrogen plus progesterone were combined into one hor-
mone therapy group because the specific type of hor-
mone therapy received did not influence adherence. For
both subjects given placebo and subjects given hormone
therapy the coefficient of determination, R2, is very low
(less than 4%) indicating that the adherence score was
not well predicted by the factors in the model.
The table is structured so that the factors are divided
into categories and sorted within category by t value
from the regression in the dataset with all subjects
combined. The most statistically significant factor in
both the placebo and hormone therapy arms of the
study was race. Greater age was strongly associated with
lower adherence for women taking hormone therapy
and was not associated with adherence for women tak-
ing placebo; the differences between study arms for this
association was significant at the P<0.0001 level using a
statistical test for interaction.
In general, factors that reflected emotional well-being
or contributed to emotional well-being (lack of money
problems and participating in groups) were associated
with greater adherence. However, adherence was higher
for women who woke frequently during the night, pos-
sibly because these women believed that hormone ther-
apy might reduce this problem.
Women in both study populations had lower adher-
ence rate if they wanted to participate in the dietary trial
and higher adherence rates if they were taking certain
types of medications: nonsteroidal anti-inflammatory,
diuretics, any combination pill, and more years of oral
contraceptives. Taking hormone therapy at baseline,
however, had a different association with adherence forTable 2 The percentage of subjects with adherence greater th
without that characteristic
Placebo
Adherence greater than 90% 72.0% (n=13,417)
Characteristic Has characteristic (n) t-va
Yes† No†
Education after high school 71.5% (5360) 72.5% (7958) −1
Current smoker 65.9% (1391) 72.7% (12,026) −4
Mammogram ever 72.3% (12,518) 68.6% (899) 1
Colonoscopy ever 73.2% (5340) 71.2% (8077) 1
Low fat diet 73.6% (4923) 71.1% (8494) 2
Multivitamins 75.2% (4150) 70.6% (9267) 4
Regular recreational physical activity 73.2% (10,018) 68.6% (3399) 4
‡ A two-sample t-test was used to determine the statistical significance of differenc
subjects without the characteristic.
† Yes indicates that the participant has the characteristic. No indicates that the partwomen in the placebo group (no association) than for
women in the hormone therapy group (it substantially
increased adherence). The difference is these associa-
tions was significant at the P<0.0001 level using the
test for interaction. Women with certain health problems
(atrial fibrillation, constipation, and higher diastolic blood
pressure) had lower adherence rates.
Association of adherence with risk The results in
Table 2 and 3 suggest that adherence is associated with
several factors likely to reduce the risk of adverse
outcomes, e.g., better healthcare behaviors and better
emotional well-being. To examine whether there was a
tendency for adherence to be associated with lower risk,
we found the correlations between adherence and pa-
tient risk for subjects taking placebo). For all outcomes
the risk increased with greater adherence. Greater adher-
ence had a correlation of 0.051 (P<0.0001) with breast
cancer risk, a correlation of 0.031 (P=0.003) with colon
cancer risk, a correlation of 0.022 (P=0.013) with the risk
of myocardial infarction, a correlation of 0.017 (P=0.047)
with the risk of stroke, and a correlation of 0.008
(P=0.36) with the risk of death.
Association of adherence with outcomes The risk-
adjusted association of outcomes with adherence on a
four point scale is shown in Figure 1 for subjects given
placebo. The group with adherence no greater than 50%
was combined with the group that had adherence less
than 80% because both groups were small and the
outcomes for the group with adherence ≤50% were not
worse than other subjects with adherence less than 80%.
As shown in the figure the hazard ratios for the two
lowest adherence groups were most elevated for myocar-
dial infarction and stroke. The level of statisticalan 90% for subjects with a characteristic and subjects
Hormone therapy
66.5% (n=13,709)
lue‡ P value Has characteristic (n) t-value‡ P value
Yes† No†
.32 0.19 66.1% (5588) 66.9% (8024) −0.94 0.34
.64 <.0001 63.2% (1395) 66.9% (12,314) −2.20 0.03
.48 0.14 66.8% (12742) 62.6% (976) 2.05 0.04
.01 0.31 67.2% (5296) 66.1% (8413) 0.24 0.81
.36 0.02 67.1% (5047) 66.1% (8662) 0.56 0.58
.84 <.0001 69.4% (4225) 65.2% (9484) 4.30 <.0001
.39 <.0001 67.3% (9966) 64.4% (3743) 2.41 0.02
es in the adherence scale between subjects with the characteristic and
icipant does not have the characteristic.
Table 3 Patient characteristics independently associated with adherence at the P<0.001 level for all subjects
Variable label All subjects R2=0.036 Placebo arm R2=0.035 Hormone arm R2=0.036
t-value P-value t-value P-value t-value P-value
Demographic
White 14.56 <.0001 10.88 <.0001 9.89 <.0001
Age −5.28 <.0001 0.89 0.37 −8.01 <.0001
Partner currently retired 4.61 <.0001 4.57 <.0001 1.78 0.075
Psychological
Emotional well being 4.83 <.0001 2.98 0.0029 3.84 0.0001
Wake up several times 4.58 <.0001 2.87 0.0042 3.65 0.0003
Fewer emotional limitations 4.48 <.0001 2.37 0.018 3.84 0.0001
Money problems −4.08 <.0001 −3.78 0.0002 −2.22 0.027
Attend clubs/lodges/groups 4.05 <.0001 2.95 0.0032 2.78 0.0055
Healthcare behaviors
Interested in dietary modification study −5.36 <.0001 −4.65 <.0001 −3.01 0.0026
Water Soluble Dietary Fiber (g) 4.20 <.0001 2.66 0.0077 3.10 0.0019
Medical treatments
Nonsteroidal anti-inflammatory 5.08 <.0001 2.41 0.016 4.44 <.0001
Diuretic 4.85 <.0001 3.68 0.0002 3.26 0.0011
Baseline hormone therapy 4.73 <.0001 −0.03 0.97 6.54 <.0001
Any combination pill 4.10 <.0001 3.12 0.0018 2.55 0.011
Years oral contraception 4.08 <.0001 3.43 0.0006 2.49 0.013
Health
Atrial fibrillation −3.66 0.0003 −1.69 0.091 −3.40 0.0007
Constipation −3.64 0.0003 −2.33 0.020 −2.86 0.0042
Diastolic blood pressure −3.37 0.0007 −0.63 0.53 −4.29 <.0001
The associated t-values and P-values are from linear regression analyses.
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The association was not statistically significant for colon
cancer, which had many fewer cases than the other
outcomes.
The association became stronger after adjusting for
the risk factors. This was expected because of the posi-
tive correlations between adherence and risk. The chi-
squared values of adherence in the Cox model before
and after adjusting for risk factors were 21.2 and 27.0 for
myocardial infarction, 7.8 and 9.5 for stroke, 14.2 and
17.4 for breast cancer, and 11.4 and 12.7 for death.
Examples of the adjusted and unadjusted hazard ratios
for adherence less than or equal to 80% versus greater
than 100% are 2.04 versus 2.31 for myocardial infarction
and 1.71 and 1.77 for breast cancer.
Although none of the individual risk factors that
predicted adherence were independent risk factors for
any outcome, we tested whether the predicted adherence
from the linear regression model was a risk factor for
MI. After adjusting for other MI risk factors but not
adjusting for actual adherence level, the p-value for
predicted adherence was 0.82.One possible explanation of the association of greater
adherence to placebo with better health outcomes is that
patients who adhere better to placebo also adhere better
to other medications. To test these association we tested
whether adherence to placebo was more associated with
better outcomes for patients taking a particular medica-
tion than it was for women not taking the medication, i.
e., we tested the statistical significance of the interaction
between adherence to placebo and taking a particular
type of medication. The medication therapeutic classes
evaluated and the number of women in the placebo
group who were taking these medications were anti-
inflammatory analgesic (n= 2675), diuretic (n= 1627),
thyroid (n= 1458), antihypertensive (n= 1447), calcium
blocker (n= 1343), antihyperlipedemic (n= 1123), beta_
blocker (n= 909), antidiabetic (n= 662), hypnotic (n= 403),
antianxiety (n= 357), narcotic analgesic (n= 277), anti-
anginal (n= 195), cardiotonic (n= 156), and anticonvulsant
(n= 120). No other types of medication were taken by
more than 100 women in the placebo group. Although we
tested the interaction of adherence with each of the 14
medication types with 5 outcomes (70 tests in all), none of
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significance at the P<0.10 level. This suggests that the
advantage of higher adherence to placebo was not due to
greater adherence to any specific, effective, commonly ta-
ken medication.
In Figure 2 there is some evidence for declining rates
of myocardial infarction and stroke as adherence in-
creased in the subjects on hormone therapy. It is pos-
sible that the phenomenon of adherence outweighs any
biological risk imparted from the use of hormone the-
rapy? The opposite was observed in the CAST study, in
which higher adherence to active therapy was associated
with more adverse outcomes [16].
However, associations between adherence and out-
come were weaker for subjects on hormone therapy than
for subjects on placebo. Based on tests for interaction
the association for subjects on placebo was significantly
stronger than the association for subjects on hormone
therapy for myocardial infarction (P=0.02), breast cancer
(P<0.0001), and death (P=0.001). There was little diffe-
rence in the association between adherence and breast
cancer for women on either type of hormone therapy
and for women only taking estrogen alone.
Discussion
Greater adherence to placebo had a substantial and





















Figure 1 Hazard ratios of placebo adherence for each of five outcommyocardial infarction, stroke, breast cancer, and morta-
lity. Greater adherence to hormone therapy had a weak
association with two outcomes (myocardial infarction
and stroke) and no significant association with others.
The more than 800 risk factors in the WHI only poorly
predicted adherence to placebo or hormone therapy and
did not account for the associations between adherence
and outcome. There was no evidence that the associ-
ation between placebo adherence and outcome was
stronger for patients taking any of the prescribed
medications most commonly used by the women in the
study. A stronger association for some medications
would be expected if placebo adherence was a marker
for adherence to this medication.
The association between adherence and outcome is
probably due to confounding factors rather than an ac-
tual effect of adherence. Our results suggest that these
confounding factors were not adequately measured by
the WHI. Since WHI is an unusually comprehensive
dataset, it is likely that few if any studies record informa-
tion that accounts for the association between adherence
and outcome.
Previous literature
Previous studies have also found an association of greater
adherence to placebo with better healthcare outcomes.
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outcomes for motor vehicle accidents and workplace
accidents [11]. Outcomes not found to be associated with
adherence include wrist, vertebral, or non vertebral
fractures [17,18].
One study analyzed the same placebo subjects as in the
present study [19]. This study found that women with
adherence to placebo less than 80% had significantly
worse outcomes than women with greater adherence. The
hazard ratios were 2.0 for hip fracture, 1.67 for cancer
death, 1.56 for all-cause mortality, and 1.45 for myocardial
infarction. The following design differences between their
study and ours may have contributed to some differences
(although no contradictions) in results: 1) Their measure
of adherence was based on all follow-up exams and ours
was based only on adherence during the first year. As a
result the previous study had a higher percentage of
subjects with adherence to placebo less than 80% (23%
versus 16% in our study). The overall adherence may have
been more subject to aspects of health that changed over
time and therefore, were not adequately measured at base-
line. 2) Their assessment of outcomes was truncated
sooner, and they had fewer events: e.g., (241 versus 463 for
myocardial infarction), (265 versus 441 for breast cancer)
and (464 versus 781 for death). 3) Their study analyzed
adherence in two groups and ours in four. 4) The previous

























Figure 2 Hazard ratios of hormone therapy adherence for each of fivevaluating the association between adherence and out-
come. Our study empirically screened more than 800 risk
factors to determine if any accounted for the association
between adherence and outcome (Additional file 1).
5) The previous study did not examine the association
between adherence to hormone therapy and outcome. We
are not aware of other studies that examined the associ-
ation between adherence to an active medication and an
outcome that the active medication was not designed to
promote. Our results suggest that these associations may
differ from the association between placebo and outcome.Conclusions
Several studies have found associations of adherence with
various diseases and mortality. This probably indicates
that adherence to placebo is a marker for other risk factors
that influence outcome. However, an exhaustive examin-
ation of the comprehensive set of risk factors in the WHI
could not identify risk factors that underlie the association
between placebo adherence and several outcomes.
Because WHI collected a high percentage of the risk
factors commonly used to predict cardiovascular diseases
and other outcomes, it is also unlikely that many other
studies collect these risk factors. The same risk factors
that confound the effects of adherence may also confound
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studies of medical treatments.
Additional file
Additional file 1: Total 971 variables. Form 2 Eligibility Screening (45).
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